Market›Health Care›Biotechnology›Biotechnology
Pelthos Therapeutics

PTHS

$25.00Feb 16, 2024 – Apr 30, 2026
Health CareBiotechnology$73M
MVM
-$8.1M
BLE
-0.600
PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Chart Start
$48.00
2024
Since 2024
-47.9%
vs SPY +43.1%
All-time High
$60.00 · Feb 2024
-58.3% from peak
MVM Rank
#489 of 589
Biotechnology
Reaction Win Rate
40%
25 of 62 events

Pelthos Therapeutics has returned -47.9% from $48.00 since 2024, trailing SPY's +43.1% over the same period. The stock hit an all-time high of $60.00 in Feb 2024 and is currently 58.3% below that level. Of 62 tracked news events, 40% produced a positive market-adjusted return.

How to use this page
1Company Research Snapshot

Expand to read Wikipedia-sourced background on the company. Click any linked term to explore it inline — no page reload.

2Company Q&A

Common questions answered from real data: performance vs SPY, market cap, profitability, CEO, dividends, and more.

3News & Events

Every dot on the chart is a news event. The return shown is market-adjusted (vs SPY). Green = stock outperformed. Red = underperformed. Dot size = magnitude of reaction.

Company Q&AShow ▼
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2025-07-04+61.1%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2026-04-03+19.0%newsUBND thành phố Hải PhòngPTHS Stock Analysis: Pelthos Therapeutics Inc. 4.23% Dip to $20.4 Key Insights - UBND thành phố Hải Phòng
2025-07-02+18.6%newsTradingViewPTHS Stock Price and Chart — AMEX:PTHS - TradingView
2025-07-02+18.6%newsStock TitanLatest PTHS News - Pelthos Therapeutics to Participate in Pipe... - Stock Titan
2025-07-02+18.6%M&AYahoo FinancePelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement - Yahoo Finance
2025-07-02+18.6%M&AYahoo FinanceLigand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - Yahoo Finance
2025-07-02+18.6%M&AStock TitanLatest PTHS News - Pelthos Therapeutics Completes Merger with ... - Stock Titan
2025-04-17+16.2%newsSeeking AlphaLigand unit Pelthos to merge with Channel Therapeutics
2026-03-19-11.9%earningsGuruFocus.comPelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ...
2026-03-19-11.9%earningsMarketBeatPelthos Therapeutics Q4 Earnings Call Highlights
2026-03-19-11.9%earningsZacksPelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates
2026-03-19-11.9%newsGlobeNewswirePelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
2026-03-19-11.9%expansionSeeking AlphaPelthos signals continued ZELSUVMI momentum and targets expanded product launches through 2027
2026-03-19-11.9%earningsSeeking AlphaPelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript
2026-03-19-11.9%earningsSeeking AlphaPelthos Therapeutics GAAP EPS of -$6.87 misses by $3.84, revenue of $9.39M beats by $0.3M
2026-03-19-11.9%earningsYahoo FinancePelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
2026-03-19-11.9%expansionInvesting.comOppenheimer raises Pelthos Therapeutics price target to $62 on launch - Investing.com
2026-03-19-11.9%newsTipRanksPelthos Highlights 2025 Results and Portfolio Expansion Progress - TipRanks
2025-12-01-11.2%newsSeeking AlphaPelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely
2025-12-01-11.2%newsSeeking AlphaPelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely - Seeking Alpha
2026-04-06+11.0%newsInvesting.comGreenleaf Peter sells Pelthos Therapeutics (PTHS) stock for $16,669 - Investing.com
2026-04-06+11.0%newsInvesting.comPauls Matthew sells Pelthos Therapeutics (PTHS) stock for $16,439 - Investing.com
2026-04-06+11.0%newsStock TitanDirector at Pelthos Therapeutics (PTHS) sells 590 shares under plan - Stock Titan
2025-11-07-10.8%M&AInvesting.comPelthos Therapeutics stock falls after acquisition of impetigo treatment - Investing.com
2025-11-07-10.8%M&AYahoo FinancePelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing - Yahoo Finance
2024-03-18-9.3%executiveSeeking AlphaChromocell appoints Frank Knuettel as CEO, removing interim status
2026-03-09+8.8%earningsMarketBeatPelthos Therapeutics (PTHS) Earnings Date and Reports 2026 - MarketBeat
2026-04-07-8.7%newsMT NewswiresTop Premarket Decliners
2026-04-07-8.7%newsStock TitanPTHS SEC Filings - Pelthos Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
2025-11-13-8.5%earningsSeeking AlphaPelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript
2025-11-13-8.5%earningsSeeking AlphaPelthos Therapeutics GAAP EPS of -$5.30
2025-11-13-8.5%newsYahoo FinancePelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results - Yahoo Finance
2026-01-05-8.1%M&AGlobeNewswirePelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - GlobeNewswire
2026-03-12+7.5%newsGlobeNewswirePelthos Therapeutics to Present at 38th Annual ROTH Conference
2025-06-27+6.7%newsSeeking AlphaChannel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting
2025-06-27+6.7%newsGlobeNewswireChannel Therapeutics Announces Reverse Common Stock Split - GlobeNewswire
2026-03-29-6.3%newsMarketBeatPelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview
2026-04-24+5.8%newsChartMillPTHS Cash Flow | PELTHOS THERAPEUTICS INC (NYSEARCA:PTHS) - ChartMill
2024-08-07-5.4%newsSeeking AlphaChromocell announces stock repurchase plan
2025-12-03+4.4%analystBenzingaThis Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
2025-07-16+3.8%analystZacks Investment ResearchWhat is the current Price Target and Forecast for Pelthos Therapeutics Inc. (PTHS) - Zacks Investment Research
2026-04-01-3.7%newsStock TitanPelthos Therapeutics (PTHS) director reports 19,108-share RSU board grant - Stock Titan
2026-04-01-3.7%newsStock TitanBoard member Todd Davis (PTHS) updates Pelthos stock grants and holdings - Stock Titan
2026-04-01-3.7%newsStock TitanBoard member Richard Malamut logs revised RSU stock awards at Pelthos (PTHS) - Stock Titan
2026-04-01-3.7%newsStock TitanDirector Ezra Friedberg (PTHS) files amended RSU equity grants - Stock Titan
2026-04-01-3.7%newsStock TitanDirector Matthew Pauls receives 25,478-share RSU grant at Pelthos (PTHS) - Stock Titan
2026-04-01-3.7%newsStock TitanPelthos Therapeutics (PTHS) CCO receives 30,518 RSUs in equity award - Stock Titan
2026-03-15-3.1%newsSeeking AlphaQuant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag
2026-03-31-2.3%newsGlobeNewswirePelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
2026-04-14-2.0%newsGlobeNewswirePelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
2025-08-18-1.6%earningsSeeking AlphaPelthos Therapeutics GAAP EPS of -$5.38
2026-01-13-1.1%newsSeeking AlphaPelthos Therapeutics raises $50 mln senior secured loan facility
2026-04-10+0.9%executiveGlobeNewswirePelthos Therapeutics Announces CFO Transition
2026-04-10+0.9%executiveSeeking AlphaPelthos Therapeutics names John M. Gay as CFO
2026-04-10+0.9%executiveQuiver QuantitativePelthos Therapeutics Inc. Appoints John M. Gay as Chief Financial Officer | PTHS Stock News - Quiver Quantitative
2026-04-10+0.9%executiveTipRanksPelthos Therapeutics Appoints John M. Gay as CFO - TipRanks
2026-04-10+0.9%executiveStock TitanPelthos elevates finance chief John Gay as CFO in leadership shift - Stock Titan
2026-04-12+0.9%executiveSahmPelthos Therapeutics Announces CFO Transition - Sahm
2026-04-20+0.8%executiveStock TitanPelthos Therapeutics (PTHS) CFO discloses 30,518 RSUs and 93,000 options - Stock Titan
2024-10-24-0.5%newsSeeking AlphaChromocell announces amendment to stock repurchase plan
2026-04-23-0.1%earningsCổng thông tin điện tử tỉnh Tây NinhPTHS Pelthos Therapeutics reports narrower than expected Q4 2025 loss, shares dip slightly following earnings release. - Slow Growth - Cổng thông tin điện tử tỉnh Tây Ninh
2026-04-23-0.1%earningsXã Thanh HàPTHS Pelthos Therapeutics reports narrower than expected Q4 2025 loss, shares dip slightly following earnings release. - Neutral Rating - Xã Thanh Hà
2024-02-16—newsSeeking AlphaChromocell stock down 11% following $7M IPO
2024-02-16—newsSeeking AlphaChromocell Therapeutics prices upsized $6.6M IPO at $6 per share
tickerdossier.comtickerdossier.substack.com